Previous 10 | Next 10 |
2023-07-25 10:22:46 ET Summary Biogen, Eisai, and Eli Lilly's Alzheimer's drugs have shown little efficacy, particularly in non-APOE4 carriers. The companies recast the data to suggest non-carriers benefitted more from their drugs, but in reality, non-carriers benefitted least as ...
2023-07-25 08:26:12 ET Biogen ( NASDAQ: BIIB ) exceeded Wall Street forecasts with its Q2 2023 results on Tuesday and announced a new cost savings program including plans to reduce about 1,000 employees as the company shifts its resources to newly approved medications. The C...
2023-07-25 07:14:52 ET Biogen press release ( NASDAQ: BIIB ): Q2 Non-GAAP EPS of $4.02 beats by $0.26 . Revenue of $2.46B (-5.0% Y/Y) beats by $100M . FY23 Outlook: Total revenue growth in mid-single digit percentage decline Y/Y. Non-GAAP EPS of $15.00-...
2023-07-24 15:08:24 ET Summary Eli Lilly and Company's share price won't stop climbing on the promise of its "miracle" diabetes and weight loss drug, Tirzepatide, and franchise. The share price is +25% so far this year, and +425% over a 5-year period. Lilly is now the world's most...
2023-07-24 10:09:27 ET When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products. These could make interesting investment opportunities. But they often hold a decent amount of risk. So, if you're a cautious investor, you ...
2023-07-23 07:54:18 ET Summary Barron’s Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies, of-which YCharts reported 25 as paying dividends. Barron’s interviews with their ten financi...
2023-07-21 16:26:19 ET McDonald’s ( MCD ) McDonald's ( MCD ), the second-largest restaurant chain by total locations, will report its Q3 earnings before the market opens on Thursday. With a bullish stance on the stock, UBS thinks MCD is well-positioned for more share ...
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023 PR Newswire Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying...
2023-07-18 08:34:40 ET Summary Positive topline results released from phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early AD. The global market for Alzheimer's disease treatments is expected to rise past $13 billion by 2030. There was statist...
2023-07-17 13:21:00 ET Complete phase 3 data released on Eli Lilly's ( NYSE: LLY ) donanemab confirmed that the Alzheimer's biologic was effective in slowing cognitive decline in early stages of the disease compared to placebo. Yet, as is the case with Biogen ( BIIB ) and Ei...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...